archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Archived ASX Releases 2008 - 2012
    up 63 when compared to the twelve months ended 30 June 2008 More 22 06 2009 Accounting treatment conversion of USD 1 5 billion funds on deposit to Australian dollars On 9 June 2009 CSL Limited ASX CSL made an announcement to the Australian Securities Exchange regarding the termination of the Talecris Biotherapieutics merger agreement More 09 06 2009 Recording of Analyst Briefing Analyst Briefing with CSL Managing Director and Chief Executive Officer Dr Brian McNamee This was recorded on June 9th 2009 following the announcement that CSL and Talecris Biotherapeutics have agreed to terminate the merger agreement More 09 06 2009 CSL and Talecris Biotherapeutics Agree to Terminate Merger Agreement CSL Limited ASX CSL and Talecris Biotherapeutics Inc announced today that they have mutually agreed to terminate their merger agreement announced on August 12 2008 under which CSL agreed to acquire Talecris for US 3 1 billion in cash More 09 06 2009 CSL announces on market share buyback CSL Limited ASX CSL today announced its intention to conduct an on market share buyback of up to 54 863 000 shares 1 This represents approximately 9 of the company s current shares on issue At an assumed price per share of approximately A 29 being CSL s last closing price on Friday 5 June this would represent a total buy back consideration of up to A 1 59 billion More 29 05 2009 CSL Receives USD180 million approximately AUD230 million Order from U S Government to Produce Novel Influenza A H1N1 Vaccine CSL Limited announced today that its US subsidiary CSL Biotherapies Inc has signed a contract with the U S Department of Health and Human Services HHS to provide Novel A H1N1 influenza vaccine antigen in bulk form More 28 05 2009 Recording of Analyst Briefing Analyst Briefing

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/page/1255923307862/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive


  • Archived ASX Releases 2008 - 2012
    Responsibility Careers Newsroom Contact CSL Home Archived ASX Releases Archived ASX Releases 2008 Releases Also in this section 2012 ASX Releases 2011 ASX Releases 2010 ASX Releases 2009 ASX Releases 2008 ASX Releases 13 10 2008 CSL Receives FTC Request for Additional Information CSL Receives FTC Request for Additional Information on its Proposed Merger with Talecris Biotherapeutics More 02 09 2008 CSL Appoints New Director CSL today announced that Mr David Anstice has been appointed a Director of the Company effective 2 September 2008 More 13 08 2008 Full Year Results for 2008 CSL Limited today announced a profit after tax of 702 million for the twelve months ended 30 June 2008 up 30 when compared to the twelve months ended 30 June 2007 On a constant currency basis profit grew 45 More 20 02 2008 CSL Half Year Results Announcement for 2007 08 CSL Limited today announced a profit after tax of 349 million for the six months ended 31 December 2007 up 36 when compared to the six months ended 31 December 2006 This included an adverse foreign currency impact of 28m when compared with the prior comparable period PCP More 10 02 2008 CSL Limited Warns Shareholders

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/page/1199979006819/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive

  • CSL Historical Financial Performance in US Dollars
    the 2012 13 financial year US dollars are the pharmaceutical industry standard currency for reporting purposes The move also reflects the increasing predominance of the Company s worldwide sales and operations in US dollars To assist investors during the transition the Company is today lodging with the Australian Securities Exchange sets of financial statements for the first half and full year financial 2012 restated in US dollars A 5 year financial summary in US dollars is also provided The financial statements have been prepared using Accounting Policies consistent with those applied in the preparation of CSL Limited s audited consolidated financial statements for these periods These accounting policies can be found in Note 1 of the CSL Limited Financial Report contained in the CSL Annual Report for the relevant period and available from the company s website www csl com au The attached financial statements are unaudited but have been subject to Agreed Upon Procedures carried out by Ernst Young We expect these to form the prior comparable period disclosures in the CSL Group Financial Statements for the half year ended 31 December 2012 to be reviewed by Ernst Young and full year ended 30 June 2013 to be audited

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255930016847/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL drug candidate in diabetes research breakthrough
    Vice President of Research at CSL This disease is reaching epidemic proportions and is a significant public health burden We are very hopeful that the antibody based drug that we have developed and tested together with Professor Eriksson will ultimately lead to a new treatment option for people with diabetes Type 2 diabetes is normally preceded by insulin resistance which is most often caused by obesity When this happens the cells no longer respond sufficiently to insulin which leads to elevated levels of blood sugar Dr Nash said insulin resistance is related to the storage of fat in the wrong places such as the muscles and in the heart although exactly how this relationship works is not fully understood What scientists do know however is that the VEGF B protein affects the transport and storage of fat in body tissue This was discovered by Professor Ulf Eriksson s research group in a study published in Nature in 2010 These findings were further developed in this latest study in which VEGF B signalling was blocked by CSL s drug candidate known as 2H10 in groups of diabetic mice and rats It s a great feeling to have published these new results said Professor Ulf Eriksson We discovered VEGF B back in 1995 and since then the VEGF B project has been a lengthy sojourn in the wilderness but now we re making one important discovery after the other A total of four related studies are reported in the Nature paper In one study mice bred to spontaneously develop diabetes were treated with 2H10 The mice subsequently developed neither insulin resistance nor diabetes The research team also crossed this mouse model with one that lacked the ability to produce VEGF B and found that the at risk offspring were protected from developing

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255929822075/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Biotherapies awarded Pandemic Preparedness Contract by US Government
    the US Government may request CSL Biotherapies to manufacture and store bulk antigen that can be used against influenza strains with pandemic potential The Company may also be called upon to develop working virus seeds for other manufacturers and to formulate fill and finish bulk stored antigen CSL Biotherapies is the only manufacturer of influenza vaccine in the Southern Hemisphere with a capacity to produce in excess of 80 million doses of vaccine per annum CSL Biotherapies is unique in that it is involved in every stage of influenza vaccine manufacture from the development of the seed viruses necessary to produce vaccine all the way through to final packaged product in syringes ready to be administered During the 2009 H1N1 pandemic CSL Biotherapies was pivotal in producing vaccine early initiating world first clinical trials and providing pandemic vaccine for vaccination programs in Australia New Zealand the United States Germany Singapore and Canada as well as to the World Health Organisation CSL Biotherapies has a long and proud history of developing and manufacturing vaccines dating back to the 1918 Spanish Flu pandemic said Dr John Anderson General Manager of CSL Biotherapies Influenza pandemics can have devastating impacts and we are very pleased to be working with the US Government in their pandemic preparedness efforts As Australia s only on shore influenza vaccine manufacturer CSL Biotherapies is already contracted by the Commonwealth Government to manufacture vaccines in the event of an influenza pandemic CSL takes its role in protecting Australia against pandemic influenza very seriously and we continually invest in our operations to remain pandemic ready said Dr Anderson This puts us in a strong position to collaborate with governments globally to prepare for a pandemic emergency Funding for the CSL Biotherapies contract is provided solely by the United States Department of

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255929640961/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited today announced Full Year Results for 2011/12.
    up A 42 million or 4 5 on a reported basis when compared to the prior comparable period This result included an unfavourable foreign exchange impact of A 108 million On a constant currency 1 basis net profit after tax grew 16 Earnings per share growth continues to benefit from current and past capital management initiatives Download this release ASX Full Year Information 0 15 Mb Additional resources The Webcast

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255929472428/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Successor to CEO Brian McNamee Announced
    and more than 30 years experience in the healthcare and biopharmaceutical industry Professor Shine said that long term succession planning for Dr McNamee had been underway for some time He said This plan is in line with our market announcement in December 2009 that Brian would continue as CEO for three to four years He said he was very pleased that the Board had been able to select a candidate of Mr Perreault s stature and capability from current management Paul was selected after consideration of a strong field of well qualified candidates The process has reconfirmed the Board s confidence in the quality and depth of CSL s global management Paul brings tremendous leadership capability to the role together with deep experience in the day to day management of CSL s global operations He has been closely involved in the development of the current strategy and we are confident he will continue the trajectory of CSL s growth and outstanding performance Professor Shine said Professor Shine said that he was pleased that Dr McNamee would continue to lead the organisation through until June 2013 Brian will run the business as normal giving us the continued benefit of his leadership right up to the hand over mid next year he said He said that both Brian and the Board felt the time was right to pass the baton to the next leadership of the Company and he wanted to acknowledge Brian s extraordinary contribution both to CSL and the local and international pharmaceutical industry Brian s achievement is the CSL you see today He and his talented team many of whom remain part of the leadership built it more or less from scratch When Brian took over in 1990 CSL was a domestic focussed government enterprise Now we are a

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255929393054/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Retirement of Director - Peter Turner
    CSL will be leaving the Company as an executive and as a consequence retiring as a director of CSL as of 17 October 2012 Mr Turner has been a director of CSL since December 2009 and has had a long and distinguished career with CSL for over 45 years Professor John Shine CSL s Chairman said Peter has made an invaluable contribution to CSL over many years as an executive

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255929304751/prdetail.htm (2014-01-05)
    Open archived version from archive